Cargando…
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity
Conventional anti-cancer drug screening is typically performed in the absence of accessory cells of the tumor microenvironment, which can profoundly alter anti-tumor drug activity. To address this major limitation, we developed the tumor cell-specific in vitro bioluminescence imaging (CS-BLI) assay....
Autores principales: | McMillin, Douglas W., Delmore, Jake, Weisberg, Ellen, Negri, Joseph M., Geer, D. Corey, Klippel, Steffen, Mitsiades, Nicholas, Schlossman, Robert L., Munshi, Nikhil C., Kung, Andrew L., Griffin, James D., Richardson, Paul G., Anderson, Kenneth C., Mitsiades, Constantine S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786785/ https://www.ncbi.nlm.nih.gov/pubmed/20228816 http://dx.doi.org/10.1038/nm.2112 |
Ejemplares similares
-
Microenvironmental Influence on Pre-Clinical Activity of Polo-Like Kinase Inhibition in Multiple Myeloma: Implications for Clinical Translation
por: McMillin, Douglas W., et al.
Publicado: (2011) -
High-throughput approaches to discover novel immunomodulatory agents for cancer
por: McMillin, Douglas W., et al.
Publicado: (2012) -
Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy
por: Richardson, Paul, et al.
Publicado: (2010) -
The Treatment of Multiple Myeloma Patients Not Eligible for Asct
por: Richardson, Paul, et al.
Publicado: (2010) -
Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)